Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods – 9 April 2024

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth Parliament, serves to regulate the manufacture, supply, and advertising of therapeutic goods in Australia, aiming to protect public health by ensuring these products are of acceptable quality and safety. This legislation fills a critical gap by establishing a robust framework for the oversight of therapeutic goods, which include medicines, medical devices, blood, and tissues, among others. The Act was introduced to address issues related to the quality, safety, and efficacy of therapeutic goods available in the market, ensuring that they meet necessary standards before being made available to the public. On 9 April 2024, Katherine Clark, as a delegate of the Secretary of the Department of Health and Aged Care, Therapeutic Goods Administration, published the revocation of several manufacturers' licences under Section 41 of the Therapeutic Goods Act 1989. The revocations were executed at the request of the manufacturers themselves, reflecting a compliance measure aimed at maintaining the integrity of the therapeutic goods market. This action underscores the policy objective of the Therapeutic Goods Administration to uphold high standards in the manufacturing and distribution of therapeutic goods within Australia.

Scope and Application

The Therapeutic Goods Act 1989 governs the regulation of therapeutic goods within Australia, impacting a broad spectrum of entities and industries. This legislation applies to manufacturers, importers, and suppliers of therapeutic goods, including medicines, medical devices, and blood products, ensuring they meet quality, safety, and efficacy standards. The Act's jurisdictional reach is national, as it is a Commonwealth Act, thereby applying uniformly across all states and territories in Australia. The revocation of manufacturing licences, as evidenced by the notice published by Katherine Clark, Delegate of the Secretary of the Department of Health and Aged Care, Therapeutic Goods Administration, pertains specifically to companies that have had their licences revoked at their own request. These companies include various entities such as CANNOPERATIONS PTY LTD, MPV PACKAGING PTY LTD, BOTANICAL RESOURCES AUSTRALIA-MANUFACTURING SERVICES PTY LTD, PFIZER AUSTRALIA PTY LTD, WILD CHILD LABORATORIES PTY LTD, and COMPLEMENTARY MEDICINES GROUP PTY LTD, each identified by their unique licence numbers and addresses. The revocation process, as outlined in Section 41(1)(e) of the Act, is a formal administrative action taken by the Secretary to ensure compliance with therapeutic goods standards and to safeguard public health.

Key Provisions

Under Section 41(1)(e) of the Therapeutic Goods Act 1989, the Secretary has the authority to revoke a licence to manufacture therapeutic goods. This particular notice pertains to the revocation of several manufacturing licences by the Therapeutic Goods Administration (TGA) at the request of the respective manufacturers. The affected companies and their revoked licences are: CANNOPERATIONS PTY LTD (Licence No. MI-2020-LI-11863-1), MPV PACKAGING PTY LTD (Licence No. MI-2013-LI-11768-1), BOTANICAL RESOURCES AUSTRALIA-MANUFACTURING SERVICES PTY LTD (Licence No. MI-2021-LI-07525-1), PFIZER AUSTRALIA PTY LTD (Licence No. MI-2021-LI-05229-1), WILD CHILD LABORATORIES PTY LTD (Licence No. MI-2013-LI-10560-1), and COMPLEMENTARY MEDICINES GROUP PTY LTD (Licence No. MI-2016-LI-07542-1). The revocation of these licences signifies that the companies are no longer authorised to manufacture therapeutic goods as per the provisions of the Therapeutic Goods Act 1989. The revocation of a manufacturing licence under the Therapeutic Goods Act 1989 imposes specific obligations on the affected companies. These companies are no longer permitted to manufacture therapeutic goods in their facilities, which includes any form of production, packaging, or distribution of therapeutic goods. They must ensure that any ongoing production or distribution activities cease immediately upon the revocation notice. The companies must also comply with any additional instructions or conditions set by the TGA, which may include the return of any therapeutic goods, equipment, or documentation related to the manufacturing activities. It is imperative that these companies adhere to the requirements to avoid any further legal complications or enforcement actions. Failure to comply with the revocation of a manufacturing licence can result in serious legal consequences. Under the Therapeutic Goods Act 1989, continued manufacturing activities by a company whose licence has been revoked can be considered an offence. Such offences may lead to both criminal and civil penalties. For criminal offences, individuals responsible for the continued manufacturing activities can face substantial fines and even imprisonment. The exact penalties depend on the severity of the breach and can be determined by the courts. Civil penalties may also be imposed, including fines and orders to rectify the breach. The maximum penalties for these offences are specified in the Act and can vary widely based on the specific circumstances of the case.